OBJECTIVE: Matrix metalloproteinase-9 (MMP-9) has been widely described to play a critical role in aneurysm development. The goal of this study was to determine the spatiotemporal changes in MMP-9 expression and abundance in the early stages of aortic dilatation during the course of thoracic aortic aneurysm (TAA) formation in a mouse model. METHODS: In this study, TAAs were surgically induced in a transgenic reporter mouse strain expressing the beta-galactosidase (beta-gal) gene under control of the MMP-9 promoter. Terminal studies were performed during the early stages of TAA development at 1 week (n = 6), 2 weeks (n = 6), and 4 weeks (n = 6) post-TAA induction surgery. Changes in aortic outer diameter were determined in vivo by video micrometry. MMP-9 transcriptional activity (beta-gal staining) and protein content (immunohistochemistry) were quantified at each time point and expressed as a percentage of unoperated reference control mice (n = 6). RESULTS: Aortic dilatation was evident at 1 week and reached maximal size at 2 weeks (21% +/- 6% increase from baseline, P < .05). MMP-9 transcriptional activity was detected at 1 week post-TAA induction (722% +/- 323%, P = .19), reached a maximum within the adventitia at 2 weeks (1770% +/- 505%, P < .05), and returned to baseline by 4 weeks (167% +/- 47%, P = .21). MMP-9 transcription at 2 weeks colocalized with fibroblasts and smooth muscle cells. MMP-9 protein content within the aortic adventitia was increased at 2 weeks post-TAA induction (413% +/- 124%, P < .05) and remained elevated at 4 weeks (222% +/- 41%, P < .05). MMP-9 staining was most intense at the adventitial-medial border and could be detected throughout the elastic media. CONCLUSIONS: These findings demonstrate a unique spatiotemporal pattern of MMP-9 transcriptional activation and protein content in the developing TAA. Colocalization studies suggest that early dilatation may be driven in part by MMP-9 produced by endogenous cells residing within the aortic vascular wall.
OBJECTIVE:Matrix metalloproteinase-9 (MMP-9) has been widely described to play a critical role in aneurysm development. The goal of this study was to determine the spatiotemporal changes in MMP-9 expression and abundance in the early stages of aortic dilatation during the course of thoracic aortic aneurysm (TAA) formation in a mouse model. METHODS: In this study, TAAs were surgically induced in a transgenic reporter mouse strain expressing the beta-galactosidase (beta-gal) gene under control of the MMP-9 promoter. Terminal studies were performed during the early stages of TAA development at 1 week (n = 6), 2 weeks (n = 6), and 4 weeks (n = 6) post-TAA induction surgery. Changes in aortic outer diameter were determined in vivo by video micrometry. MMP-9 transcriptional activity (beta-gal staining) and protein content (immunohistochemistry) were quantified at each time point and expressed as a percentage of unoperated reference control mice (n = 6). RESULTS: Aortic dilatation was evident at 1 week and reached maximal size at 2 weeks (21% +/- 6% increase from baseline, P < .05). MMP-9 transcriptional activity was detected at 1 week post-TAA induction (722% +/- 323%, P = .19), reached a maximum within the adventitia at 2 weeks (1770% +/- 505%, P < .05), and returned to baseline by 4 weeks (167% +/- 47%, P = .21). MMP-9 transcription at 2 weeks colocalized with fibroblasts and smooth muscle cells. MMP-9 protein content within the aortic adventitia was increased at 2 weeks post-TAA induction (413% +/- 124%, P < .05) and remained elevated at 4 weeks (222% +/- 41%, P < .05). MMP-9 staining was most intense at the adventitial-medial border and could be detected throughout the elastic media. CONCLUSIONS: These findings demonstrate a unique spatiotemporal pattern of MMP-9 transcriptional activation and protein content in the developing TAA. Colocalization studies suggest that early dilatation may be driven in part by MMP-9 produced by endogenous cells residing within the aortic vascular wall.
Authors: R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson Journal: J Clin Invest Date: 2000-06 Impact factor: 14.808
Authors: John R Barbour; Robert E Stroud; Abigail S Lowry; Leslie L Clark; Allyson M Leone; Jeffery A Jones; Francis G Spinale; John S Ikonomidis Journal: J Thorac Cardiovasc Surg Date: 2006-10 Impact factor: 5.209
Authors: John S Ikonomidis; William C Gibson; Jonathan Gardner; Sarah Sweterlitsch; Robert P Thompson; Rupak Mukherjee; Francis G Spinale Journal: J Surg Res Date: 2003-11 Impact factor: 2.192
Authors: Andrea Huwiler; el-Sayed Akool; Armaz Aschrafi; Farid M A Hamada; Josef Pfeilschifter; Wolfgang Eberhardt Journal: J Biol Chem Date: 2003-10-01 Impact factor: 5.157
Authors: Jeffrey A Jones; Robert E Stroud; Elizabeth C O'Quinn; Laurel E Black; Jeremy L Barth; John A Elefteriades; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Francis G Spinale; John S Ikonomidis Journal: Circ Cardiovasc Genet Date: 2011-10-18
Authors: Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro Journal: Int J Mol Sci Date: 2020-12-20 Impact factor: 5.923
Authors: Jeffrey A Jones; Juozas A Zavadzkas; Eileen I Chang; Nina Sheats; Christine Koval; Robert E Stroud; Francis G Spinale; John S Ikonomidis Journal: J Thorac Cardiovasc Surg Date: 2010-03-09 Impact factor: 5.209
Authors: Debra L Rateri; Frank M Davis; Anju Balakrishnan; Deborah A Howatt; Jessica J Moorleghen; William N O'Connor; Richard Charnigo; Lisa A Cassis; Alan Daugherty Journal: Am J Pathol Date: 2014-07-16 Impact factor: 4.307
Authors: Jeffrey A Jones; John R Barbour; Robert E Stroud; Shenikqua Bouges; Shelly L Stephens; Francis G Spinale; John S Ikonomidis Journal: J Vasc Res Date: 2008-04-23 Impact factor: 1.934